Regeneron Pharmaceuticals Q2 2026 earnings surpass estimates, driven by Dupixent sales
Regeneron Pharmaceuticals reported second‑quarter 2026 results that beat Wall Street expectations. Revenue rose 17 % year‑over‑year to $4.29 billion, exceeding the $3.82 billion forecast. The company posted non‑GAAP earnings per share of $14.29, well above the $10.26 estimate. Dupixent, Regeneron's flagship eczema drug, generated $6.0 billion in global net sales, up 38 % from the prior year, while the high‑dose version of the eye drug Eylea saw U.S. sales climb 52 % to $596 million. Regeneron also announced that it has fully repaid the Sanofi Development Balance, clearing the outstanding amount owed to its partner. These strong results were highlighted by analysts, who noted the potential for continued margin expansion and an upbeat outlook for the second half of the year.
Entities: Amy Baker · Dupixent · Eylea · Larry F. Mazza · MVB Financial Corp. · Mike Sumbs · Regeneron Pharmaceuticals, Inc. · Sanofi
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Net interest income rose 13% sequentially to $32.3 million in Q2 2026. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [○ 1 SOURCE] MVB Financial reported Q2 2026 net income of $12.3 million, or $0.93 per diluted share. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [○ 1 SOURCE] The loan‑to‑deposit ratio at quarter end was just below 80%. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [○ 1 SOURCE] MVB Financial recorded a $10 million pre‑tax gain on an existing fintech investment during Q2 2026. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [○ 1 SOURCE] Fully tax-equivalent net interest margin expanded 43 basis points to 4.16% from the prior quarter. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [○ 1 SOURCE] Loans increased 3% in the quarter, a 12% annualized growth, marking the fifth consecutive quarter of loan growth. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [● 2 SOURCES] MVB Financial held its Q2 2026 earnings conference call on July 28, 2026. (multiple)
- [○ 1 SOURCE] Deposits rose 7.4% in the quarter, with non‑interest‑bearing deposits up 5.7%. (d383e316-82c8-425e-a01a-cf77d7e134fc)
- [○ 1 SOURCE] Regeneron fully repaid the Sanofi Development Balance in Q2 2026. (Regeneron beats quarterly estimates on eczema drug strength, shares rise)
- [● 2 SOURCES] Regeneron reported Q2 2026 revenue of $4.29 billion, up 17 % year‑over‑year. (Regeneron Pharmaceuticals Q2 2026 earnings beat estimates; Regeneron Pharmaceuticals Releases Q2 2026 Financial Results)
- [● 2 SOURCES] Regeneron posted non‑GAAP EPS of $14.29 for Q2 2026, beating the $10.26 estimate. (Regeneron beats quarterly estimates on eczema drug strength, shares rise; Regeneron Pharmaceuticals Releases Q2 2026 …)
- [● 2 SOURCES] Dupixent generated $6.0 billion in global net sales in Q2 2026, up 38 % year‑over‑year. (Regeneron beats quarterly estimates on eczema drug strength, shares rise; Regeneron Pharmaceuticals Releases Q2 2026 …)